Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis
Epistemonikos ID: 89e66c41f010ece4189d642a1fb4bc642aed3613
First added on: Jan 24, 2026